I learned that a clear category can still leave the important relationship unexplained.

I began in healthcare business research, where a large part of the work involved making a complicated market understandable to someone deciding where to invest attention. A category was useful: it let a reader see an unfamiliar activity in relation to something already known. Over time I learned that the same convenience could become a weakness. Once the category appeared in a portfolio chart, people could forget the dependencies that had been compressed into its label. My career has increasingly concerned the questions needed to bring those dependencies back into the decision.

After completing a business administration degree at the fictional Valcerin School of Management in June 1989, I joined Orvanel Health Advisory that August. I worked in a five-person analyst team. My responsibility was to examine business evidence, reconcile definitions and explain the limits of what a comparison could establish. I did not have authority over a client's medicines, investment or professional conclusions. Those boundaries mattered because a clear commercial presentation could otherwise appear to settle questions that belonged to people with different expertise and responsibilities.

Engagement leadership followed in April 1996. By 2002 I led eleven colleagues through two direct reports, with C$1.1 million in advisory-delivery expense. The firm's C$31 million fee revenue and 120-person workforce described the company, not my personal remit. I became more interested in how an institution used a recommendation after the advisory assignment ended. A portfolio category could be accepted quickly while its qualifications received much less attention. I wanted a role in which I could revisit that interpretation as subsequent choices made its consequences clearer.

I joined the invented Vaurenne Therapeutics in July 2003 as head of portfolio planning. The move put me inside an established-medicines business and made me accountable for the continuity of its strategic account. In 2008 I described nine brands as evidence of diversification before examining how they reached institutional buyers. Six relied on one procurement route. My classification had given the number of names more weight than the common dependency beneath them. Correcting the research and the portfolio account cost C$620,000. The mistake did not make those medicines deficient; it made my explanation of the business less adequate than it should have been.

The correction changed how I approached wider corporate strategy after my promotion in June 2010. In a 2016 expansion assessment, two proposed markets appeared to broaden the business geographically. The model attributed 56% of C$135 million in annual sales at maturity to one proposed distribution group. These were estimates, not achieved revenue. I supported preparing one market first, with C$2.4 million in assessment and commercial work, while preserving the longer-term ambition. Geography had changed in the proposal, but the commercial dependence remained concentrated enough to affect the choice.

I became CSO in September 2017. My current thirty-eight-person function works through five direct reports with C$9.6 million in delegated 2026 expense. The company recorded C$860 million revenue in 2025 and employs 1850 people. Those figures establish context, while medical, scientific, quality, safety, regulatory and capital authorities remain separate. I present strategy in an executive capacity to the board. I have no statutory directorship to add to that exposure, and the earlier engagement-director title was an employment designation.

The later cases continue to test what portfolio breadth means. Fourteen initiatives needed to be distinguished as nine early development activities and five established-medicine extensions. A proposed acquisition with C$84 million in trailing annual revenue carried 45% through the same institutional purchasing group and did not provide the diversification its therapeutic-area labels suggested. A smaller established portfolio still needed its support requirements represented while long-term options were considered. In each case, I wanted the strategic account to remain useful when an attractive headline was examined more closely.

I now write about those distinctions because they make judgement more assessable than a broad claim about growth. I retain the expense, the objection and the interpretation I had to revise. All events on this demonstration site are invented, including the colleague voices and career record. They show how a pharmaceutical strategist could prepare an honest public account from authorised evidence. They do not establish real product performance, medical competence or an appointment that another institution should accept without verification.